@article{oai:repo.qst.go.jp:00081509,
 author = {Ono, Takashi and Yamamoto, Naoyoshi and Nomoto, Akihiro and Nakajima, Mio and Isozaki, Yuka and Kasuya, Goro and Ishikawa, Hitoshi and Nemoto, Kenji and Tsuji, Hiroshi and Takashi, Ono and Naoyoshi, Yamamoto and Akihiro, Nomoto and Mio, Nakajima and Yuka, Isozaki and Goro, Kasuya and Hitoshi, Ishikawa and Kenji, Nemoto and Hiroshi, Tsuji},
 issue = {1},
 journal = {Cancers},
 month = {Jan},
 note = {Abstract: Background: The purpose of the present study was to evaluate the efficacy and safety of single-fraction carbon-ion radiotherapy (CIRT) in patients with non-small cell lung cancer. Methods:Patients with histologically confirmed non-small cell lung cancer, stage T1-2N0M0, and treated with single-fraction CIRT (50Gy (relative biological effectiveness)) between June 2011 and April 2016 were identified in our database and retrospectively analyzed. Toxicity was evaluated using the Common Terminology Criteria for Adverse Events version 4.0. Results: The study included 57 patients,22 (38.6%) of whom had inoperable cancer. The median age was 75 years (range: 42–94 years), and
the median follow-up time was 61 months (range: 6–97 months). The 3- and 5-year overall survival rates were 91.2% and 81.7%, respectively. All survivors were followed up for more than three years.The 3- and 5-year local control rates were 96.4% and 91.8%, respectively. No case of  grade 2 pneumonitis was recorded. Conclusions: This study suggests that single-fraction CIRT for T1-2N0M0 non-small cell lung cancer patients is feasible and can be considered as one of the treatment choices,especially in medically inoperable patients.},
 title = {Long Term Results of Single-Fraction Carbon-Ion Radiotherapy for Non-small Cell Lung Cancer},
 volume = {13},
 year = {2021}
}